Mount Sinai Breast Cancer Care
Breast cancer care at the Mount Sinai Health System encompasses innovative treatments and research-driven approaches for all patients. With a multidisciplinary team of highly-skilled physicians and practitioners, we offer comprehensive services, including state-of-the-art screening, novel therapies, and clinical trials at convenient locations throughout the New York City area; among these locations is the renowned Dubin Breast Center of The Tisch Cancer Institute.
Please call 844-MD-CANCER or email mscancer@mountsinai.org to learn how our experts can provide the best possible breast health care for your patients.
Why Mount Sinai
At Mount Sinai, your patients will have access to the most advanced treatments, including those available only through clinical trials.
For example, Amy Tiersten, MD, led a multicenter, phase I/II trial of dual HER2 antibodies in combination with palbociclib and anastrozole—a non-chemotherapy, all biologic approach to the treatment of HR+, HER2+ metastatic breast cancer. Positive responses will guide similar future protocols.
Hanna Irie, MD, PhD, has collaborated with chemical biologists to develop novel therapeutics that target drug-resistant disease. The collaborations have led to the discovery of drug candidates that inhibit growth and induce death of aggressive triple-negative breast cancer (TNBC) cells. These novel therapeutics will be tested in patient cancer-derived TNBC mouse models developed by Dr. Irie and Elisa Port, MD.
Additionally, the Mount Sinai Breast Tumor Biospecimen Repository has banked more than 500 breast tumor specimens.
Cancer programs at the Dubin Breast Center and other Mount Sinai locations are part of The Tisch Cancer Institute (a National Cancer Institute-designated cancer center), our Cancer Centers of Excellence, and our Cancer Network.